<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Pathog</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Pathog</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plospath</journal-id><journal-title-group><journal-title>PLoS Pathogens</journal-title></journal-title-group><issn pub-type="ppub">1553-7366</issn><issn pub-type="epub">1553-7374</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7546461</article-id><article-id pub-id-type="doi">10.1371/journal.ppat.1008902</article-id><article-id pub-id-type="publisher-id">PPATHOGENS-D-20-01059</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Viral Diseases</subject><subj-group><subject>Covid 19</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Coronaviruses</subject><subj-group><subject>SARS coronavirus</subject><subj-group><subject>SARS CoV 2</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Coronaviruses</subject><subj-group><subject>SARS coronavirus</subject><subj-group><subject>SARS CoV 2</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Coronaviruses</subject><subj-group><subject>SARS coronavirus</subject><subj-group><subject>SARS CoV 2</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Coronaviruses</subject><subj-group><subject>SARS coronavirus</subject><subj-group><subject>SARS CoV 2</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Respiratory Infections</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Respiratory Disorders</subject><subj-group><subject>Respiratory Infections</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pulmonology</subject><subj-group><subject>Respiratory Disorders</subject><subj-group><subject>Respiratory Infections</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and Immunization</subject><subj-group><subject>Vaccine Development</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and Immunization</subject><subj-group><subject>Vaccine Development</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Public and Occupational Health</subject><subj-group><subject>Preventive Medicine</subject><subj-group><subject>Vaccination and Immunization</subject><subj-group><subject>Vaccine Development</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Epidemiology</subject><subj-group><subject>Pandemics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Genomics</subject><subj-group><subject>Microbial Genomics</subject><subj-group><subject>Viral Genomics</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial Genomics</subject><subj-group><subject>Viral Genomics</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Virology</subject><subj-group><subject>Viral Genomics</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Virus Testing</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Epidemiology</subject></subj-group></subj-group></article-categories><title-group><article-title>Preparedness needs research: How fundamental science and international collaboration accelerated the response to COVID-19</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kinsella</surname><given-names>Cormac M.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-4324-5967</contrib-id><name><surname>Santos</surname><given-names>Pauline Dianne</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-9083-4102</contrib-id><name><surname>Postigo-Hidalgo</surname><given-names>Ignacio</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7688-6288</contrib-id><name><surname>Folgueiras-Gonz&#x000e1;lez</surname><given-names>Alba</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-1306-5853</contrib-id><name><surname>Passchier</surname><given-names>Tim Casper</given-names></name><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-1135-0244</contrib-id><name><surname>Szillat</surname><given-names>Kevin P.</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-0483-426X</contrib-id><name><surname>Akello</surname><given-names>Joyce Odeke</given-names></name><xref ref-type="aff" rid="aff006"><sup>6</sup></xref><xref ref-type="aff" rid="aff007"><sup>7</sup></xref><xref ref-type="aff" rid="aff008"><sup>8</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9898-4997</contrib-id><name><surname>&#x000c1;lvarez-Rodr&#x000ed;guez</surname><given-names>Beatriz</given-names></name><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-0005-9761</contrib-id><name><surname>Mart&#x000ed;-Carreras</surname><given-names>Joan</given-names></name><xref ref-type="aff" rid="aff009"><sup>9</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Laboratory of Experimental Virology, Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Charit&#x000e9; &#x02013;Universit&#x000e4;tsmedizin Berlin, Corporate Member of Freie Universit&#x000e4;t Berlin, Humboldt-Universit&#x000e4;t zu Berlin, and Berlin Institute of Health, Institute of Virology, Berlin, Germany</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Department of Discovery and Technology, MSD Animal Health, Boxmeer, the Netherlands</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>Institute for Infectious Diseases, University of Bern, Bern, Switzerland</addr-line></aff><aff id="aff007"><label>7</label>
<addr-line>Biology Division, Spiez Laboratory, Swiss Federal Office for Civil Protection, Spiez, Switzerland</addr-line></aff><aff id="aff008"><label>8</label>
<addr-line>Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland</addr-line></aff><aff id="aff009"><label>9</label>
<addr-line>Laboratory of Clinical and Epidemiological Virology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Lakdawala</surname><given-names>Seema</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>University of Pittsburgh, UNITED STATES</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p>The authors of this manuscript have the following competing interests: Alba Folgueiras-Gonz&#x000e1;lez is employed at MSD Animal Health, a commercial company.</p></fn><corresp id="cor001">* E-mail: <email>c.m.kinsella@amsterdamumc.nl</email></corresp></author-notes><pub-date pub-type="epub"><day>9</day><month>10</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2020</year></pub-date><volume>16</volume><issue>10</issue><elocation-id>e1008902</elocation-id><permissions><copyright-statement>&#x000a9; 2020 Kinsella et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Kinsella et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="ppat.1008902.pdf"/><abstract><p>The first cluster of patients suffering from coronavirus disease 2019 (COVID-19) was identified on December 21, 2019, and as of July 29, 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections have been linked with 664,333 deaths and number at least 16,932,996 worldwide. Unprecedented in global societal impact, the COVID-19 pandemic has tested local, national, and international preparedness for viral outbreaks to the limits. Just as it will be vital to identify missed opportunities and improve contingency planning for future outbreaks, we must also highlight key successes and build on them. Concomitant to the emergence of a novel viral disease, there is a &#x02018;research and development gap&#x02019; that poses a threat to the overall pace and quality of outbreak response during its most crucial early phase. Here, we outline key components of an adequate research response to novel viral outbreaks using the example of SARS-CoV-2. We highlight the exceptional recent progress made in fundamental science, resulting in the fastest scientific response to a major infectious disease outbreak or pandemic. We underline the vital role of the international research community, from the implementation of diagnostics and contact tracing procedures to the collective search for vaccines and antiviral therapies, sustained by unique information sharing efforts.</p></abstract><funding-group><funding-statement>European Union&#x02019;s Horizon 2020 research and innovation programme, via the Marie Sk&#x00142;odowska-Curie Actions grant agreement no. 721367 (HONOURs). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="1"/><page-count count="12"/></counts><custom-meta-group><custom-meta id="outbreaks"><meta-name>Outbreaks</meta-name><meta-value>COVID-19</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Since 1950, the global population has tripled to 7.8 billion, with expansion in meat consumption and living area thought to increase human exposure to microbes infecting wildlife, with occasional &#x02018;spillover&#x02019; to people [<xref rid="ppat.1008902.ref001" ref-type="bibr">1</xref>]. Approximately 60% of human infectious diseases are zoonotic [<xref rid="ppat.1008902.ref002" ref-type="bibr">2</xref>] (transmitted from animals). Zoonoses capable of human-to-human transmission can emerge as catastrophic diseases; acquired immunodeficiency syndrome (AIDS) alone has killed an estimated 32 million [<xref rid="ppat.1008902.ref003" ref-type="bibr">3</xref>], whilst coronavirus disease 2019 (COVID-19) has caused the largest global economic crisis since the Great Depression [<xref rid="ppat.1008902.ref004" ref-type="bibr">4</xref>].</p><p>Speed of response is critical with respect to mitigation of infectious outbreaks, since in a susceptible population, the number of infections may increase exponentially. The aim of outbreak preparedness is therefore to ensure that contingency planning is in place beforehand to avoid delays associated with an ad hoc response, thus enabling intervention whilst case numbers are low. For well-established diseases such as measles in humans, this preparation includes systems for (1) <bold>detection</bold> by routine surveillance, (2) <bold>confirmation</bold> by designated specialist laboratories, and (3) <bold>response</bold>, which will be uniquely tailored to the situation [<xref rid="ppat.1008902.ref005" ref-type="bibr">5</xref>]. Contrastingly, spillover of a novel pathogen entails additional complications caused by gaps in fundamental knowledge and validated technical resources. Since this &#x02018;research and development gap&#x02019; impinges on the effectiveness and rate of response, it is an important factor that must be considered in the context of preparedness [<xref rid="ppat.1008902.ref006" ref-type="bibr">6</xref>].</p></sec><sec id="sec002"><title>The novel pathogen research and development landscape</title><p>An outbreak caused by a novel pathogen requires a rapid research effort across the experimental and clinical spectrum. As an outbreak response progresses, research and development continue to play an integral role at each stage (summarised in <xref ref-type="fig" rid="ppat.1008902.g001">Fig 1</xref>). Here, we describe the various aspects of this research and development landscape using COVID-19 as an example, with emphasis on recent factors that have accelerated the response to the outbreak.</p><fig id="ppat.1008902.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1008902.g001</object-id><label>Fig 1</label><caption><title>Key components of the research response to viral outbreaks are shown as a simplified workflow.</title><p>Factors complicating the delivery of each step are annotated on the left.</p></caption><graphic xlink:href="ppat.1008902.g001"/></fig></sec><sec id="sec003"><title>The detection of COVID-19 and the discovery of SARS-CoV-2</title><p>When unusually high incidence of a clinical syndrome is observed in a group of patients (a cluster), there may be suspicion of a shared infection, which could constitute an outbreak. Initial investigation must therefore identify what pathogen is present in order to confirm an outbreak and kick-start a response. The first cluster of patients with COVID-19 was identified on December 21, 2019, after which investigations were carried out by the Chinese Center for Disease Control and Prevention and the National Institute of Viral Disease Control and Prevention [<xref rid="ppat.1008902.ref007" ref-type="bibr">7</xref>,<xref rid="ppat.1008902.ref008" ref-type="bibr">8</xref>]. A diagnostic panel covering 22 human pathogens was run on these patients, with universally negative results [<xref rid="ppat.1008902.ref008" ref-type="bibr">8</xref>]. This immediately raised suspicion of a novel pathogen, requiring discovery methods.</p><p>Virus discovery methods include polymerase chain reaction (PCR) assays targeting conserved genome regions specific to all members of a taxonomic family (potentially even unknown ones), attempted virus isolation in cell culture, microscopy to study the virion morphology, and metagenomic analysis of human samples for the identification of the pathogen. These analyses were carried out on samples from the initial COVID-19 cluster and published in a remarkably short 34 days [<xref rid="ppat.1008902.ref008" ref-type="bibr">8</xref>] (<xref ref-type="fig" rid="ppat.1008902.g002">Fig 2</xref>). Virus was grown in primary human airway epithelial cell cultures, which provide optimal substrates for coronavirus replication [<xref rid="ppat.1008902.ref009" ref-type="bibr">9</xref>,<xref rid="ppat.1008902.ref010" ref-type="bibr">10</xref>], and transmission electron microscopy images were generated, showing the spherical virion and surface spikes characteristic of coronaviruses [<xref rid="ppat.1008902.ref008" ref-type="bibr">8</xref>]. The first severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomes were published online on January 10, 2020 (<xref ref-type="fig" rid="ppat.1008902.g002">Fig 2</xref>), 20 days after cluster detection (GISAID accessions EPI_ISL_402119 and EPI_ISL_402121), and phylogenetic analyses showed the virus was a relative of both severe acute respiratory syndrome coronavirus (SARS-CoV-1) [<xref rid="ppat.1008902.ref007" ref-type="bibr">7</xref>] (i.e., the etiological agent of the 2002&#x02013;2004 SARS outbreak) and a strain sampled from a bat [<xref rid="ppat.1008902.ref011" ref-type="bibr">11</xref>], confirming a novel zoonotic virus outbreak and kick-starting research efforts worldwide.</p><fig id="ppat.1008902.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1008902.g002</object-id><label>Fig 2</label><caption><title>The changing dynamics of research response: contrasting the SARS-CoV-1 and SARS-CoV-2 outbreaks.</title><p>COVID-19, coronavirus disease 2019; PCR, polymerase chain reaction; PHEIC, Public Health Emergency of International Concern; SARS-CoV-1, severe acute respiratory syndrome coronavirus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; WHO, World Health Organization.</p></caption><graphic xlink:href="ppat.1008902.g002"/></fig></sec><sec id="sec004"><title>Testing, tracing, and isolating</title><p>When facing a novel pathogen, an immediate research priority is the development of diagnostic assays to detect infected individuals. Testing in the clinic ensures that COVID-19 patients are separated from SARS-CoV-2 negative individuals and confirms viral shedding has ceased before discharge. Testing in the community uncovers viral transmission dynamics to support control policies, such as prevalence in vulnerable demographics [<xref rid="ppat.1008902.ref012" ref-type="bibr">12</xref>], case fatality [<xref rid="ppat.1008902.ref013" ref-type="bibr">13</xref>], or the viral basic reproduction number [<xref rid="ppat.1008902.ref014" ref-type="bibr">14</xref>] (i.e., <italic>R</italic><sub>0</sub>, the average number of further infections arising from 1 case in a na&#x000ef;ve population). The first specific PCR assay for SARS-CoV-2 RNA was designed, validated, and published [<xref rid="ppat.1008902.ref015" ref-type="bibr">15</xref>] within 13 days of the first genome being made available online (<xref ref-type="fig" rid="ppat.1008902.g002">Fig 2</xref>). Loop-mediated isothermal amplification (LAMP) assays, which can rapidly and sensitively detect viral RNA or cDNA with minimal equipment, were also validated on patient samples only 2 months after the outbreak emerged [<xref rid="ppat.1008902.ref016" ref-type="bibr">16</xref>&#x02013;<xref rid="ppat.1008902.ref018" ref-type="bibr">18</xref>].</p><p>Tracing viral spread by identifying infected individuals and their potential contacts enables interventions such as selective quarantine, a method that has long been deployed as a firebreak to epidemic spread. Contact tracing is being applied during the current pandemic; however, with the surge in COVID-19 cases, it has become increasingly challenging to conduct [<xref rid="ppat.1008902.ref019" ref-type="bibr">19</xref>]. Technological solutions in the form of privacy-protecting open-source contact tracing apps have emerged rapidly, such as the TraceTogether app of Singapore, released in March 2020. This uses Bluetooth to log other app users that come in close proximity, storing their phone numbers in encrypted form for 14 days, data which are only accessible by the Health Ministry after approach by a contact tracer. With Apple and Google engaged in a similar effort [<xref rid="ppat.1008902.ref020" ref-type="bibr">20</xref>], in the future, such software solutions may be integrated with standard phone operating systems and become status quo tools during epidemics.</p><p>In addition to diagnostic testing and contact tracing, genomic epidemiology can today be used to describe the evolution of a virus in time and space, uncovering transmission patterns [<xref rid="ppat.1008902.ref021" ref-type="bibr">21</xref>]. Importantly, this is now a real-time tool rather than a retrospective one. Whereas the first SARS-CoV-1 genome was published over 6 months into the 2002&#x02013;2004 outbreak [<xref rid="ppat.1008902.ref022" ref-type="bibr">22</xref>] (<xref ref-type="fig" rid="ppat.1008902.g002">Fig 2</xref>), nearly 5 months into the SARS-CoV-2 pandemic, over 27,000 complete genomes could be downloaded from the GISAID sequence repository (<ext-link ext-link-type="uri" xlink:href="http://www.gisaid.org/">www.gisaid.org</ext-link>). Technological advances in high-throughput sequencing have made this possible, first via short-read technologies such as Solexa (now Illumina), first available in 2006, and second by the 2014 commercial implementation of nanopore sequencing by Oxford Nanopore Technologies. These platforms are commonly used to investigate SARS-CoV-2 transmission clusters, for example, by the COVID-19 Genomics UK (COG-UK) consortium [<xref rid="ppat.1008902.ref023" ref-type="bibr">23</xref>], which has sequenced thousands of virus genomes during the pandemic. Due to a relatively low entry price, nanopore technology has been decisive in improving accessibility to sequencing, reinforced by initiatives including the ARTIC Network [<xref rid="ppat.1008902.ref024" ref-type="bibr">24</xref>], who quickly developed and published primer schemes and protocols for amplicon sequencing of whole SARS-CoV-2 genomes. Analysis of this wealth of data has also been made more accessible by online tools; for example, the Nextstrain platform [<xref rid="ppat.1008902.ref025" ref-type="bibr">25</xref>] is being used to integrate genomic, geographical, and temporal data to visualise patterns of SARS-CoV-2 spread, whilst CoV-GLUE, an online resource created using the Genes Linked by Underlying Evolution (GLUE) [<xref rid="ppat.1008902.ref026" ref-type="bibr">26</xref>] software environment, focuses on identifying and tracking new variants.</p></sec><sec id="sec005"><title>Utilising the genome: Fundamental research and development</title><p>A viral genome sequence is a launchpad for a range of parallel research goals aiming to deliver technical resources and fundamental knowledge about a new pathogen. The genome provides the sequences of protein-coding genes, which are used to safely produce pure stocks of individual viral proteins. The gene sequence is first amplified from a clinical sample or viral culture using PCR or is synthetically constructed. The DNA is delivered to cells, which produce (express) the protein encoded by the gene. Viral proteins are used in the generation of traditional antibody-based diagnostic assays, such as enzyme-linked immunosorbent assays (ELISAs), which are designed to detect viral proteins in patient samples or patient antibodies against the virus [<xref rid="ppat.1008902.ref027" ref-type="bibr">27</xref>]. Although PCR is considered the gold standard for laboratory diagnosis of an active SARS-CoV-2 infection [<xref rid="ppat.1008902.ref028" ref-type="bibr">28</xref>], serological assays can detect historical infections and play a key role in determining population attack rates and potentially protective immunity levels [<xref rid="ppat.1008902.ref029" ref-type="bibr">29</xref>,<xref rid="ppat.1008902.ref030" ref-type="bibr">30</xref>]. Lateral flow assays (LFAs) are used as rapid tests for prior viral exposure and were first reported 2 months after cluster identification [<xref rid="ppat.1008902.ref031" ref-type="bibr">31</xref>&#x02013;<xref rid="ppat.1008902.ref033" ref-type="bibr">33</xref>].</p><p>Whilst the amino acid sequence of a protein can be accurately predicted from the nucleotide sequence of its encoding gene, the protein conformational structure that determines its function cannot, and must be solved using structural biology techniques. Hardware and data processing performance revolutions in recent years have dramatically accelerated the generation of high-resolution structures; only 2 months after the first SARS-CoV-2 genome was released, a 3.5 &#x000c5; resolution cryogenic electron microscopy (cryo-EM) structure of the spike protein was published [<xref rid="ppat.1008902.ref034" ref-type="bibr">34</xref>], revealing differences to SARS-CoV-1 that preclude the binding of some anti-SARS-CoV-1 antibodies. This was followed in short order by structures including the cellular receptor ACE2 [<xref rid="ppat.1008902.ref035" ref-type="bibr">35</xref>] bound to the spike protein [<xref rid="ppat.1008902.ref036" ref-type="bibr">36</xref>], the SARS-CoV-2 nucleocapsid RNA-binding domain [<xref rid="ppat.1008902.ref037" ref-type="bibr">37</xref>], and the SARS-CoV-2 main protease [<xref rid="ppat.1008902.ref038" ref-type="bibr">38</xref>]. This structural information is useful for in silico modelling of protein&#x02013;protein interactions and high-throughput computational screening of chemical compounds with potential antiviral properties. Another remarkable approach to find drug targets exploited expression of SARS-CoV-2 proteins in human cells, followed by separation of the viral proteins (and bound host proteins) from the host background. Identification of bound host proteins by mass spectrometry revealed a number of druggable candidates that may represent therapeutic targets [<xref rid="ppat.1008902.ref039" ref-type="bibr">39</xref>].</p><p>In vivo studies such as those in livestock, frugivorous bats, and companion animals are necessary to establish their potential role in forming viral reservoirs and to provide data that are informative on the possible pathways of SARS-CoV-2 transmission from its wild reservoir to humans [<xref rid="ppat.1008902.ref040" ref-type="bibr">40</xref>,<xref rid="ppat.1008902.ref041" ref-type="bibr">41</xref>]. Furthermore, nonhuman primate models will be key to expediting preclinical evaluation of vaccines and other therapeutics for use in humans [<xref rid="ppat.1008902.ref042" ref-type="bibr">42</xref>,<xref rid="ppat.1008902.ref043" ref-type="bibr">43</xref>]. Establishment of viral cultures is vital for numerous downstream applications, including generating these in vivo infection models for therapeutic testing [<xref rid="ppat.1008902.ref044" ref-type="bibr">44</xref>], antiviral screening [<xref rid="ppat.1008902.ref045" ref-type="bibr">45</xref>], and fundamental virus characterisation [<xref rid="ppat.1008902.ref046" ref-type="bibr">46</xref>]. Traditionally, a clinical sample containing replication competent virus would be required; however, access to samples for researchers in countries without active cases is often logistically difficult in the early phases of an outbreak. Today, only a genome sequence is required&#x02014;synthetic DNA technology allows the reconstruction of viral genomes in artificial vectors&#x02014;from which viable infectious RNA can be produced and replicating virus rescued. The first such SARS-CoV-2 culture was achieved only 1 week after delivery of synthetic DNA constructs spanning the genome [<xref rid="ppat.1008902.ref047" ref-type="bibr">47</xref>] and reported 42 days after the first genome became available. This technology offers a powerful platform to carry out reverse genetic approaches using genetic engineering to study genotype-to-phenotype relationships and the function of viral components, and also enables validation of diagnostic tests in the absence of clinical specimens [<xref rid="ppat.1008902.ref015" ref-type="bibr">15</xref>].</p></sec><sec id="sec006"><title>Delivering pharmaceutical interventions to the clinic</title><p>The future trajectory of the SARS-CoV-2 pandemic is uncertain; however, elimination of the virus may depend on the availability of antiviral treatments and vaccines. Delivery of novel pharmaceutical interventions from conception to clinic is a prolonged process with numerous practical and regulatory hurdles to cross, necessitating short-term stopgaps. Repurposing of drugs already approved for human usage is an attractive option: their production is already optimised and upscaled, and they have known safety and bioavailability data, allowing human clinical trials to proceed rapidly after testing of in vitro efficacy. However, the repurposing of approved drugs can have major consequences in outbreak situations, causing acute shortages and rendering them unavailable to patients using them for the licensed indication [<xref rid="ppat.1008902.ref048" ref-type="bibr">48</xref>]. Furthermore, medications can have potentially serious side effects, and emergency use approval may entail an uncertain risk/benefit profile, as seen with the example of hydroxychloroquine, which recently had its emergency use authorisation (EUA) revoked by the United States Food and Drug Administration (FDA) [<xref rid="ppat.1008902.ref049" ref-type="bibr">49</xref>].</p><p>Clinical trials of therapeutic drugs involving hundreds of COVID-19 patients were ongoing by early February [<xref rid="ppat.1008902.ref050" ref-type="bibr">50</xref>]. During March and April, numerous compounds were identified that either have direct action on SARS-CoV-2 in vitro [<xref rid="ppat.1008902.ref045" ref-type="bibr">45</xref>,<xref rid="ppat.1008902.ref051" ref-type="bibr">51</xref>&#x02013;<xref rid="ppat.1008902.ref053" ref-type="bibr">53</xref>] or may have indirect action via host proteins [<xref rid="ppat.1008902.ref039" ref-type="bibr">39</xref>,<xref rid="ppat.1008902.ref054" ref-type="bibr">54</xref>], paving the way for in vivo efficacy trials (<xref ref-type="fig" rid="ppat.1008902.g001">Fig 1</xref>). Furthermore, on the basis of 2 clinical trials, the FDA granted an EUA of remdesivir for COVID-19 treatment on May 1, 2020 [<xref rid="ppat.1008902.ref055" ref-type="bibr">55</xref>]. This was the first direct antiviral approval, just over 4 months into the outbreak.</p><p>Delivery of neutralising antibodies (nAbs) to patients early in disease is another treatment option. Serum from convalescent COVID-19 patients contains anti-SARS-CoV-2 antibodies, and donated serum can be infused to acutely ill patients [<xref rid="ppat.1008902.ref056" ref-type="bibr">56</xref>,<xref rid="ppat.1008902.ref057" ref-type="bibr">57</xref>]. Other options include products containing purified polyclonal antibodies from the pooled sera of COVID-19 survivors [<xref rid="ppat.1008902.ref058" ref-type="bibr">58</xref>], through to the identification and characterisation of monoclonal nAbs, since these have the potential to be produced in large quantities and delivered as immunotherapy. By February, a SARS-CoV-1 nAb (CR3022) was reported to bind the receptor-binding domain of SARS-CoV-2 spike protein [<xref rid="ppat.1008902.ref059" ref-type="bibr">59</xref>]; however, it was later shown not to cross-neutralise the virus [<xref rid="ppat.1008902.ref060" ref-type="bibr">60</xref>]. In early April, an antibody (S309) from a SARS-CoV-1 survivor was found to neutralise SARS-CoV-2 [<xref rid="ppat.1008902.ref061" ref-type="bibr">61</xref>], followed in May by a humanised antibody (47D11) capable of blocking infection with both SARS-CoV-1 and SARS-CoV-2 in vitro [<xref rid="ppat.1008902.ref062" ref-type="bibr">62</xref>]. Also in May, a team demonstrated in vivo protection against high-dose SARS-CoV-2 challenge in Syrian hamsters after injection of a human monoclonal nAb [<xref rid="ppat.1008902.ref063" ref-type="bibr">63</xref>], whilst another reported identification of 19 SARS-CoV-2 nAbs [<xref rid="ppat.1008902.ref064" ref-type="bibr">64</xref>]. This was accomplished by isolating individual B cells reacting to native-like SARS-CoV-2 spike protein, followed by expression of the encoded antibodies and virus neutralisation assays. Importantly, highly potent nAbs were found that targeted different regions of the spike protein, implying suitability as a cocktail therapy with reduced risk of viral escape.</p><p>Vaccines are used to safely increase immunity levels against pathogens in populations in order to protect individuals and reduce pathways to viral spread. For SARS-CoV-2, a remarkably fast and broad vaccine development response was initiated, with the first candidate reaching human trials only 86 days after cluster identification [<xref rid="ppat.1008902.ref065" ref-type="bibr">65</xref>], over 6 times faster than the first SARS-CoV-1 human vaccine trial [<xref rid="ppat.1008902.ref066" ref-type="bibr">66</xref>] (<xref ref-type="fig" rid="ppat.1008902.g002">Fig 2</xref>). At the time of writing, 35 candidates had reached human trials, with 122 more in preclinical development [<xref rid="ppat.1008902.ref067" ref-type="bibr">67</xref>]. A range of vaccine platforms (different core approaches to elicit antibody-based immunity and their associated manufacturing pipelines) are being trialled [<xref rid="ppat.1008902.ref068" ref-type="bibr">68</xref>]. Amongst them are next-generation techniques like mRNA vaccination [<xref rid="ppat.1008902.ref065" ref-type="bibr">65</xref>], which requires relatively little development time after viral genome sequencing. If successfully tested and deployed, these novel concepts may establish themselves more firmly within the vaccine ecosystem and potentially accelerate vaccine development beyond the SARS-CoV-2 pandemic. However, the implementation of novel pharmaceutical interventions will ultimately be subject to the normal technical challenges involved with upscaling production to meet massive demand and will be dependent on the availability of appropriate production lines [<xref rid="ppat.1008902.ref068" ref-type="bibr">68</xref>]. Many of the novel vaccine approaches currently being trialled have never been manufactured at this scale, suggesting unforeseen scalability issues may place future roadblocks.</p></sec><sec id="sec007"><title>Information, property, and knowledge sharing</title><p>Against the backdrop of technological advancements that have boosted outbreak research capacity in recent years, key paradigm shifts in information sharing have also occurred, dramatically increasing how quickly and widely new results and data are received by other researchers and the public. In a rapidly evolving situation, maximum data utility is achieved by prompt release. The pace of viral genome publication during crises was highlighted as a problem during the 2014&#x02013;2016 Ebola outbreak [<xref rid="ppat.1008902.ref069" ref-type="bibr">69</xref>], yet arguably a sea change has occurred since. Furthermore, databases have emerged that compile COVID-19 publications and data resources [<xref rid="ppat.1008902.ref070" ref-type="bibr">70</xref>] or provide daily updates on outbreak data worldwide [<xref rid="ppat.1008902.ref071" ref-type="bibr">71</xref>&#x02013;<xref rid="ppat.1008902.ref074" ref-type="bibr">74</xref>], accessible to all. For researchers, the open access <italic>bioRxiv</italic> and <italic>medRxiv</italic> preprint servers (launched in 2013 and 2019, respectively) have become invaluable resources for the rapid dissemination of results, hosting a combined 7,060 articles by July 29, 2020. The cost of this speed is the absence of peer review, which can sometimes result in the publication of data falling below a necessary quality standard. Encouragingly, this openness has not been limited to academic spheres; many major technology companies including Intel, Microsoft, and Amazon have temporarily granted open access to their patent libraries for SARS-CoV-2-related research as part of the &#x02018;Open COVID Pledge&#x02019; [<xref rid="ppat.1008902.ref075" ref-type="bibr">75</xref>] to encourage innovation via sharing of intellectual property. Some pharmaceutical companies have also made similar moves, from AbbVie (North Chicago, USA) agreeing not to enforce patent rights on a drug in COVID-19 trials [<xref rid="ppat.1008902.ref076" ref-type="bibr">76</xref>] to Roche (Basel, Switzerland) sharing the composition of a buffer in their diagnostic kit with the Dutch government [<xref rid="ppat.1008902.ref077" ref-type="bibr">77</xref>]. Numerous community-driven efforts have also sprouted, from 3D printing and donation of personal protective equipment [<xref rid="ppat.1008902.ref078" ref-type="bibr">78</xref>] to the repurposing of company production lines to manufacture and donate essential materials such as hand sanitiser [<xref rid="ppat.1008902.ref079" ref-type="bibr">79</xref>].</p><p>Timely and high-quality scientific research relies on knowledge sharing between teams with varying expertise and facilities, making connectivity a keystone component of research preparedness for outbreaks. Whilst the World Health Organization (WHO) plays a crucial role in coordinating global research efforts in response to the COVID-19 pandemic, preexisting networks and formal consortia of trusted partners can immediately coordinate to form focus groups and share resources [<xref rid="ppat.1008902.ref015" ref-type="bibr">15</xref>]; several of these have been formed in response to major epidemics of recent years (<xref rid="ppat.1008902.t001" ref-type="table">Table 1</xref>). Some of these, such as Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE) [<xref rid="ppat.1008902.ref080" ref-type="bibr">80</xref>] and HONOURs [<xref rid="ppat.1008902.ref081" ref-type="bibr">81</xref>], specifically train research preparedness concepts to the next generation of scientists. An advantage of larger networks is the ability to coordinate multi-armed studies with unified procedures and centralised administration, in order to maximise sample size and achieve consensus faster. For this purpose, WHO launched the Solidarity clinical trial for testing COVID-19 treatments [<xref rid="ppat.1008902.ref082" ref-type="bibr">82</xref>], which involves over 100 countries and intends to complete 80% faster than a typical randomised clinical trial. Representative national ethics committees supported by WHO, funding agencies, and relevant collaborative research consortia provided statements guiding the conduct of COVID-19 research, which helps to standardise and expedite ethical research [<xref rid="ppat.1008902.ref083" ref-type="bibr">83</xref>]. Another important contribution of international collaborations, such as the COVID-19 Clinical Research Coalition (CRC) (<xref rid="ppat.1008902.t001" ref-type="table">Table 1</xref>), is the acceleration of COVID-19 research in low-to-middle-income countries (LMIC) where research resources, laboratory facilities, and manufacturing infrastructures are commonly limited relative to high-income countries [<xref rid="ppat.1008902.ref084" ref-type="bibr">84</xref>].</p><table-wrap id="ppat.1008902.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1008902.t001</object-id><label>Table 1</label><caption><title>A selection of the many networks and consortia conducting research into SARS-CoV-2 and COVID-19.</title></caption><alternatives><graphic id="ppat.1008902.t001g" xlink:href="ppat.1008902.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Networks</th><th align="left" rowspan="1" colspan="1">Focus</th><th align="left" rowspan="1" colspan="1">Website</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">ACTIV</td><td align="left" rowspan="1" colspan="1">Accelerating COVID-19 Therapeutic Interventions and Vaccines</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://www.nih.gov/research-training/medical-research-initiatives/activ">https://www.nih.gov/research-training/medical-research-initiatives/activ</ext-link></td></tr><tr><td align="left" rowspan="1" colspan="1">ARTIC Network</td><td align="left" rowspan="1" colspan="1">Real-time molecular epidemiology for outbreak response</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://artic.network/">https://artic.network/</ext-link></td></tr><tr><td align="left" rowspan="1" colspan="1">CEPI</td><td align="left" rowspan="1" colspan="1">Coalition for Epidemic Preparedness Innovations</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://cepi.net/">https://cepi.net/</ext-link></td></tr><tr><td align="left" rowspan="1" colspan="1">COMPARE</td><td align="left" rowspan="1" colspan="1">COllaborative Management Platform for detection and Analyses of (Re-)emerging and foodborne outbreaks in Europe</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://www.compare-europe.eu/">https://www.compare-europe.eu/</ext-link></td></tr><tr><td align="left" rowspan="1" colspan="1">COPCOV</td><td align="left" rowspan="1" colspan="1">Chloroquine/ hydroxychloroquine prevention of Coronavirus Disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://www.tropmedres.ac/covid-19/copcov">https://www.tropmedres.ac/covid-19/copcov</ext-link></td></tr><tr><td align="left" rowspan="1" colspan="1">COV-IRT</td><td align="left" rowspan="1" colspan="1">COVID-19 International Research Team</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://covirt19.org/">https://covirt19.org/</ext-link></td></tr><tr><td align="left" rowspan="1" colspan="1">COVID-19 CRC</td><td align="left" rowspan="1" colspan="1">COVID-19 Clinical Research Coalition</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://covid19crc.org/">https://covid19crc.org/</ext-link></td></tr><tr><td align="left" rowspan="1" colspan="1">ECRAID</td><td align="left" rowspan="1" colspan="1">European Clinical Research Alliance on Infectious Diseases</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://www.ecraid.eu/">https://www.ecraid.eu/</ext-link></td></tr><tr><td align="left" rowspan="1" colspan="1">eMERGE</td><td align="left" rowspan="1" colspan="1">Electronic Medical Records and Genomics</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://emerge-network.org/">https://emerge-network.org/</ext-link></td></tr><tr><td align="left" rowspan="1" colspan="1">GLOPID-R</td><td align="left" rowspan="1" colspan="1">Global Research Collaboration for Infectious Disease Preparedness</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://www.glopid-r.org/">https://www.glopid-r.org/</ext-link></td></tr><tr><td align="left" rowspan="1" colspan="1">HONOURs</td><td align="left" rowspan="1" colspan="1">Host switching pathogens, infectious outbreaks, and zoonosis</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://www.honours.eu/">https://www.honours.eu/</ext-link></td></tr><tr><td align="left" rowspan="1" colspan="1">IDCRC</td><td align="left" rowspan="1" colspan="1">Infectious Diseases Clinical Research Consortium</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://med.emory.edu/departments/medicine/divisions/infectious-diseases/idcrc/index.htm">https://med.emory.edu/departments/medicine/divisions/infectious-diseases/idcrc/index.htm</ext-link></td></tr><tr><td align="left" rowspan="1" colspan="1">INITIATE</td><td align="left" rowspan="1" colspan="1">Innate-Immunometablism as Antiviral Target</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://initiate-itn.eu/">https://initiate-itn.eu/</ext-link></td></tr><tr><td align="left" rowspan="1" colspan="1">ISARIC</td><td align="left" rowspan="1" colspan="1">International Severe Acute Respiratory and emerging Infection Consortium</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://isaric.tghn.org/">https://isaric.tghn.org/</ext-link></td></tr><tr><td align="left" rowspan="1" colspan="1">PANDORA</td><td align="left" rowspan="1" colspan="1">Pan-African Network For Rapid Research, Response and Preparedness for Infectious Diseases Epidemics</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://pandora.tghn.org/">https://pandora.tghn.org/</ext-link></td></tr><tr><td align="left" rowspan="1" colspan="1">PREPARE</td><td align="left" rowspan="1" colspan="1">Platform for European Preparedness Against (Re-)emerging Epidemics</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://www.prepare-europe.eu/">https://www.prepare-europe.eu/</ext-link></td></tr><tr><td align="left" rowspan="1" colspan="1">RECOVER</td><td align="left" rowspan="1" colspan="1">Understand the COVID-19 pandemic through clinical research in order to transform patient care and public health responses</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://www.recover-europe.eu/">https://www.recover-europe.eu/</ext-link></td></tr><tr><td align="left" rowspan="1" colspan="1">Solidarity</td><td align="left" rowspan="1" colspan="1">International clinical trial to help find an effective treatment for COVID-19, launched by WHO and partners</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments</ext-link></td></tr><tr><td align="left" rowspan="1" colspan="1">VIRUS-X</td><td align="left" rowspan="1" colspan="1">Viral metagenomics for innovation value</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://virus-x.eu/">http://virus-x.eu/</ext-link></td></tr><tr><td align="left" rowspan="1" colspan="1">ZAPI</td><td align="left" rowspan="1" colspan="1">Zoonotic Anticipation and Preparedness Initiative</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://www.imi.europa.eu/projects-results/project-factsheets/zapi">https://www.imi.europa.eu/projects-results/project-factsheets/zapi</ext-link></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>ACTIV, Accelerating COVID-19 Therapeutic Interventions and Vaccines; CEPI, Coalition for Epidemic Preparedness Innovations; COMPARE, COllaborative Management Platform for detection and Analyses of (Re-)emerging and foodborne outbreaks in Europe; COPCOV, Chloroquine/ hydroxychloroquine prevention of Coronavirus Disease (COVID-19) in the healthcare setting; COVID-19, coronavirus disease 2019; COVID-19 CRC, COVID-19 Clinical Research Coalition; COV-IRT, COVID-19 International Research Team; ECRAID, European Clinical Research Alliance on Infectious Diseases; eMERGE, Electronic Medical Records and Genomics; GLOPID-R, Global Research Collaboration for Infectious Disease Preparedness; IDCRC, Infectious Diseases Clinical Research Consortium; INITIATE, Innate-Immunometablism as Antiviral Target; ISARIC, International Severe Acute Respiratory and emerging Infection Consortium; PANDORA, Pan-African Network For Rapid Research, Response and Preparedness for Infectious Diseases Epidemics; PREPARE, Platform for European Preparedness Against (Re-)emerging Epidemics; RECOVER, Rapid European COVID-19 Emergency Response research; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; WHO, World Health Organization; ZAPI, Zoonotic Anticipation and Preparedness Initiative.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec008"><title>Outlook</title><p>The SARS-CoV-2 pandemic has been an unprecedented test of novel pathogen outbreak preparedness, revealing strengths and weaknesses in all domains. As we have highlighted here, research capacity to respond to novel outbreaks is at an all-time high. The massive threat that viral outbreaks pose to lives and economies underscores the need to build on this success by promoting fundamental research capacity and networks of collaboration.</p></sec></body><back><ack><p>We thank all investigators and early stage researchers associated with the HONOURs programme for their enthusiasm and feedback, particularly Dr Lia van der Hoek as coordinator. We also thank Dr Robert Gifford, Dr Christian Beuret, Alexis Hoste, and Dr Mathieu Claireaux for specific feedback on the manuscript. <xref ref-type="fig" rid="ppat.1008902.g001">Fig 1</xref> was created with <ext-link ext-link-type="uri" xlink:href="http://biorender.com/">BioRender.com</ext-link>.</p></ack><ref-list><title>References</title><ref id="ppat.1008902.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Plowright</surname><given-names>RK</given-names></name>, <name><surname>Parrish</surname><given-names>CR</given-names></name>, <name><surname>McCallum</surname><given-names>H</given-names></name>, <name><surname>Hudson</surname><given-names>PJ</given-names></name>, <name><surname>Ko</surname><given-names>AI</given-names></name>, <name><surname>Graham</surname><given-names>AL</given-names></name>, <etal>et al</etal>
<article-title>Pathways to zoonotic spillover</article-title>. <source>Nat Rev Microbiol</source>. <year>2017</year>;<volume>15</volume>:<fpage>502</fpage>&#x02013;<lpage>510</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro.2017.45</pub-id>
<?supplied-pmid 28555073?><pub-id pub-id-type="pmid">28555073</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Taylor</surname><given-names>LH</given-names></name>, <name><surname>Latham</surname><given-names>SM</given-names></name>, <name><surname>Woolhouse</surname><given-names>MEJ</given-names></name>. <article-title>Risk factors for human disease emergence.</article-title>
<source>Philos Trans R Soc B Biol Sci</source>. <year>2001</year>;<volume>356</volume>:<fpage>983</fpage>&#x02013;<lpage>989</lpage>.</mixed-citation></ref><ref id="ppat.1008902.ref003"><label>3</label><mixed-citation publication-type="other">Joint United Nations Programme on HIV/AIDS. Global HIV &#x00026; AIDS statistics&#x02014;2019 fact sheet. 2019. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.unaids.org/en/resources/fact-sheet">https://www.unaids.org/en/resources/fact-sheet</ext-link>.</mixed-citation></ref><ref id="ppat.1008902.ref004"><label>4</label><mixed-citation publication-type="other">International Monetary Fund. World Economic Outlook, April 2020: The Great Lockdown. In: World Economic Outlook Reports. 2020. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.imf.org/en/Publications/WEO/Issues/2020/04/14/weo-april-2020">https://www.imf.org/en/Publications/WEO/Issues/2020/04/14/weo-april-2020</ext-link>.</mixed-citation></ref><ref id="ppat.1008902.ref005"><label>5</label><mixed-citation publication-type="other">World Health Organization. Guidelines for epidemic preparedness and response to measles outbreaks. Geneva; 1999.</mixed-citation></ref><ref id="ppat.1008902.ref006"><label>6</label><mixed-citation publication-type="other">World Health Organization. R&#x00026;D Blueprint. 2016. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/teams/blueprint">https://www.who.int/teams/blueprint</ext-link>.</mixed-citation></ref><ref id="ppat.1008902.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Tan</surname><given-names>W</given-names></name>, <name><surname>Zhao</surname><given-names>X</given-names></name>, <name><surname>Ma</surname><given-names>X</given-names></name>, <name><surname>Wang</surname><given-names>W</given-names></name>, <name><surname>Niu</surname><given-names>P</given-names></name>, <name><surname>Xu</surname><given-names>W</given-names></name>, <etal>et al</etal>
<article-title>Notes from the field: a novel coronavirus genome identified in a cluster of pneumonia cases&#x02014;Wuhan, China 2019&#x02212;2020.</article-title>
<source>China CDC Wkly.</source>
<year>2020</year>;<volume>2</volume>:<fpage>61</fpage>&#x02013;<lpage>62</lpage>.</mixed-citation></ref><ref id="ppat.1008902.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Zhu</surname><given-names>N</given-names></name>, <name><surname>Zhang</surname><given-names>D</given-names></name>, <name><surname>Wang</surname><given-names>W</given-names></name>, <name><surname>Li</surname><given-names>X</given-names></name>, <name><surname>Yang</surname><given-names>B</given-names></name>, <name><surname>Song</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>A novel coronavirus from patients with pneumonia in China, 2019.</article-title>
<source>N Engl J Med</source>. <year>2020</year>;<volume>382</volume>:<fpage>727</fpage>&#x02013;<lpage>733</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2001017</pub-id>
<?supplied-pmid 31978945?><pub-id pub-id-type="pmid">31978945</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Pyrc</surname><given-names>K</given-names></name>, <name><surname>Sims</surname><given-names>AC</given-names></name>, <name><surname>Dijkman</surname><given-names>R</given-names></name>, <name><surname>Jebbink</surname><given-names>M</given-names></name>, <name><surname>Long</surname><given-names>C</given-names></name>, <name><surname>Deming</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Culturing the unculturable: human coronavirus HKU1 infects, replicates, and produces progeny virions in human ciliated airway epithelial cell cultures</article-title>. <source>J Virol</source>. <year>2010</year>;<volume>84</volume>:<fpage>11255</fpage>&#x02013;<lpage>11263</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00947-10</pub-id>
<?supplied-pmid 20719951?><pub-id pub-id-type="pmid">20719951</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Jonsdottir</surname><given-names>HR</given-names></name>, <name><surname>Dijkman</surname><given-names>R</given-names></name>. <article-title>Coronaviruses and the human airway: a universal system for virus-host interaction studies Coronaviruses: emerging and re-emerging pathogens in humans and animals Susanna Lau Emerging viruses.</article-title>
<source>Virol J.</source>
<year>2016</year>;<volume>13</volume>:<fpage>1</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1186/s12985-015-0456-4</pub-id>
<?supplied-pmid 26728778?><pub-id pub-id-type="pmid">26728778</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Zhou</surname><given-names>P</given-names></name>, <name><surname>Yang</surname><given-names>X</given-names></name>, <name><surname>Lou</surname><given-names>WXG</given-names></name>, <name><surname>Hu</surname><given-names>B</given-names></name>, <name><surname>Zhang</surname><given-names>L</given-names></name>, <name><surname>Zhang</surname><given-names>W</given-names></name>, <etal>et al</etal>
<article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title>. <source>Nature</source>. <year>2020</year>;<volume>579</volume>:<fpage>270</fpage>&#x02013;<lpage>273</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id>
<?supplied-pmid 32015507?><pub-id pub-id-type="pmid">32015507</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Baggett</surname><given-names>TP</given-names></name>, <name><surname>Keyes</surname><given-names>H</given-names></name>, <name><surname>Sporn</surname><given-names>N</given-names></name>, <name><surname>Gaeta</surname><given-names>JM</given-names></name>. <article-title>Prevalence of SARS-CoV-2 infection in residents of a large homeless shelter in Boston</article-title>. <source>J Am Med Assoc</source>. <year>2020</year>.</mixed-citation></ref><ref id="ppat.1008902.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Verity</surname><given-names>R</given-names></name>, <name><surname>Okell</surname><given-names>LC</given-names></name>, <name><surname>Dorigatti</surname><given-names>I</given-names></name>, <name><surname>Winskill</surname><given-names>P</given-names></name>, <name><surname>Whittaker</surname><given-names>C</given-names></name>, <name><surname>Imai</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>Estimates of the severity of coronavirus disease 2019: a model-based analysis.</article-title>
<source>Lancet Infect Dis</source>. <year>2020</year>.</mixed-citation></ref><ref id="ppat.1008902.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>Q</given-names></name>, <name><surname>Guan</surname><given-names>X</given-names></name>, <name><surname>Wu</surname><given-names>P</given-names></name>, <name><surname>Wang</surname><given-names>X</given-names></name>, <name><surname>Zhou</surname><given-names>L</given-names></name>, <name><surname>Tong</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Early transmission dynamics in Wuhan, China, of novel coronavirus&#x02013;infected pneumonia</article-title>. <source>N Engl J Med</source>. <year>2020</year>;<volume>382</volume>:<fpage>1199</fpage>&#x02013;<lpage>1207</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2001316</pub-id>
<?supplied-pmid 31995857?><pub-id pub-id-type="pmid">31995857</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Corman</surname><given-names>VM</given-names></name>, <name><surname>Landt</surname><given-names>O</given-names></name>, <name><surname>Kaiser</surname><given-names>M</given-names></name>, <name><surname>Molenkamp</surname><given-names>R</given-names></name>, <name><surname>Meijer</surname><given-names>A</given-names></name>, <name><surname>Chu</surname><given-names>DK</given-names></name>, <etal>et al</etal>
<article-title>Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.</article-title>
<source>Eur Secur.</source>
<year>2020</year>;<volume>25</volume>:<fpage>2000045</fpage>.</mixed-citation></ref><ref id="ppat.1008902.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>L</given-names></name>, <name><surname>Wu</surname><given-names>S</given-names></name>, <name><surname>Hao</surname><given-names>X</given-names></name>, <name><surname>Dong</surname><given-names>X</given-names></name>, <name><surname>Mao</surname><given-names>L</given-names></name>, <name><surname>Pelechano</surname><given-names>V</given-names></name>, <etal>et al</etal>
<article-title>Rapid detection of COVID-19 coronavirus using a reverse transcriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic platform.</article-title>
<source>Clin Chem</source>. <year>2020</year>;<volume>66</volume>:<fpage>975</fpage>&#x02013;<lpage>977</lpage>. <pub-id pub-id-type="doi">10.1093/clinchem/hvaa102</pub-id>
<?supplied-pmid 32315390?><pub-id pub-id-type="pmid">32315390</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Odiwuor</surname><given-names>N</given-names></name>, <name><surname>Xiong</surname><given-names>J</given-names></name>, <name><surname>Sun</surname><given-names>L</given-names></name>, <name><surname>Nyaruaba</surname><given-names>RO</given-names></name>, <name><surname>Wei</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Rapid molecular detection of SARS-CoV-2 (COVID-19) virus RNA using colorimetric LAMP.</article-title>
<source>medRxiv</source>. <year>2020</year>.</mixed-citation></ref><ref id="ppat.1008902.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Ben-Assa</surname><given-names>N</given-names></name>, <name><surname>Naddaf</surname><given-names>R</given-names></name>, <name><surname>Gefen</surname><given-names>T</given-names></name>, <name><surname>Capucha</surname><given-names>T</given-names></name>, <name><surname>Hajjo</surname><given-names>H</given-names></name>, <name><surname>Mandelbaum</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>SARS-CoV-2 on-the-spot virus detection directly from patients.</article-title>
<source>medRxiv.</source>
<year>2020</year>.</mixed-citation></ref><ref id="ppat.1008902.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Ferretti</surname><given-names>L</given-names></name>, <name><surname>Wymant</surname><given-names>C</given-names></name>, <name><surname>Kendall</surname><given-names>M</given-names></name>, <name><surname>Zhao</surname><given-names>L</given-names></name>, <name><surname>Nurtay</surname><given-names>A</given-names></name>, <name><surname>Abeler-D&#x000f6;rner</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing</article-title>. <source>Science</source>. <year>2020</year>;<volume>368</volume>:<fpage>eabb6936</fpage>
<pub-id pub-id-type="doi">10.1126/science.abb6936</pub-id>
<?supplied-pmid 32234805?><pub-id pub-id-type="pmid">32234805</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref020"><label>20</label><mixed-citation publication-type="other">Google Company Announcements. 2020. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.blog.google/inside-google/company-announcements/apple-and-google-partner-covid-19-contact-tracing-technology/">https://www.blog.google/inside-google/company-announcements/apple-and-google-partner-covid-19-contact-tracing-technology/</ext-link>.</mixed-citation></ref><ref id="ppat.1008902.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Dellicour</surname><given-names>S</given-names></name>, <name><surname>Durkin</surname><given-names>K</given-names></name>, <name><surname>Hong</surname><given-names>SL</given-names></name>, <name><surname>Vanmechelen</surname><given-names>B</given-names></name>, <name><surname>Mart&#x000ed;-Carreras</surname><given-names>J</given-names></name>, <name><surname>Gill</surname><given-names>MS</given-names></name>, <etal>et al</etal>
<article-title>A phylodynamic workflow to rapidly gain insights into the dispersal history and dynamics of SARS-CoV-2 lineages.</article-title>
<source>bioRxiv.</source>
<year>2020</year>.</mixed-citation></ref><ref id="ppat.1008902.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Marra</surname><given-names>MA</given-names></name>, <name><surname>Jones</surname><given-names>SJM</given-names></name>, <name><surname>Astell</surname><given-names>CR</given-names></name>, <name><surname>Holt</surname><given-names>RA</given-names></name>, <name><surname>Brooks-Wilson</surname><given-names>A</given-names></name>, <name><surname>Butterfield</surname><given-names>YSN</given-names></name>, <etal>et al</etal>
<article-title>The genome sequence of the SARS-associated coronavirus</article-title>. <source>Science</source>. <year>2003</year>;<volume>300</volume>:<fpage>1399</fpage>&#x02013;<lpage>1404</lpage>. <pub-id pub-id-type="doi">10.1126/science.1085953</pub-id>
<?supplied-pmid 12730501?><pub-id pub-id-type="pmid">12730501</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref023"><label>23</label><mixed-citation publication-type="other">COVID-19 Genomics UK Consortium. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.cogconsortium.uk/">https://www.cogconsortium.uk/</ext-link>.</mixed-citation></ref><ref id="ppat.1008902.ref024"><label>24</label><mixed-citation publication-type="other">ARTICnetwork. Available from: <ext-link ext-link-type="uri" xlink:href="https://artic.network/">https://artic.network/</ext-link>.</mixed-citation></ref><ref id="ppat.1008902.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Hadfield</surname><given-names>J</given-names></name>, <name><surname>Megill</surname><given-names>C</given-names></name>, <name><surname>Bell</surname><given-names>SM</given-names></name>, <name><surname>Huddleston</surname><given-names>J</given-names></name>, <name><surname>Potter</surname><given-names>B</given-names></name>, <name><surname>Callender</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Nextstrain: real-time tracking of pathogen evolution</article-title>. <source>Bioinformatics</source>
<year>2018</year>;<volume>34</volume>:<fpage>4121</fpage>&#x02013;<lpage>4123</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/bty407</pub-id>
<?supplied-pmid 29790939?><pub-id pub-id-type="pmid">29790939</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Singer</surname><given-names>JB</given-names></name>, <name><surname>Thomson</surname><given-names>EC</given-names></name>, <name><surname>McLauchlan</surname><given-names>J</given-names></name>, <name><surname>Hughes</surname><given-names>J</given-names></name>, <name><surname>Gifford</surname><given-names>RJ</given-names></name>. <article-title>GLUE: a flexible software system for virus sequence data</article-title>. <source>BMC Bioinformatics</source>
<year>2018</year>;<volume>19</volume>:<fpage>532</fpage> Available from: <ext-link ext-link-type="uri" xlink:href="https://bmcbioinformatics.biomedcentral.com/articles/10.1186/s12859-018-2459-9">https://bmcbioinformatics.biomedcentral.com/articles/10.1186/s12859-018-2459-9</ext-link>. <pub-id pub-id-type="doi">10.1186/s12859-018-2459-9</pub-id>
<?supplied-pmid 30563445?><pub-id pub-id-type="pmid">30563445</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Stadlbauer</surname><given-names>D</given-names></name>, <name><surname>Amanat</surname><given-names>F</given-names></name>, <name><surname>Chromikova</surname><given-names>V</given-names></name>, <name><surname>Jiang</surname><given-names>K</given-names></name>, <name><surname>Strohmeier</surname><given-names>S</given-names></name>, <name><surname>Arunkumar</surname><given-names>GA</given-names></name>, <etal>et al</etal>
<article-title>SARS-CoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup.</article-title>
<source>Curr Protoc Microbiol.</source>
<year>2020</year>;<volume>57</volume>:<fpage>e100</fpage>
<pub-id pub-id-type="doi">10.1002/cpmc.100</pub-id>
<?supplied-pmid 32302069?><pub-id pub-id-type="pmid">32302069</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref028"><label>28</label><mixed-citation publication-type="other">World Health Organization. Interim guidance: Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. 2020. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117">https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117</ext-link>.</mixed-citation></ref><ref id="ppat.1008902.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Spellberg</surname><given-names>B</given-names></name>, <name><surname>Haddix</surname><given-names>M</given-names></name>, <name><surname>Lee</surname><given-names>R</given-names></name>, <name><surname>Butler-Wu</surname><given-names>S</given-names></name>, <name><surname>Holtom</surname><given-names>P</given-names></name>, <name><surname>Yee</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Community prevalence of SARS-CoV-2 among patients with influenzalike illnesses presenting to a Los Angeles Medical Center in March 2020</article-title>. <source>J Am Med Assoc</source>. <year>2020</year>.</mixed-citation></ref><ref id="ppat.1008902.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Bendavid</surname><given-names>E</given-names></name>, <name><surname>Mulaney</surname><given-names>B</given-names></name>, <name><surname>Sood</surname><given-names>N</given-names></name>, <name><surname>Shah</surname><given-names>S</given-names></name>, <name><surname>Ling</surname><given-names>E</given-names></name>, <name><surname>Bromley-Dulfano</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>COVID-19 antibody seroprevalence in Santa Clara County, California.</article-title>
<source>medRxiv.</source>
<year>2020</year>.</mixed-citation></ref><ref id="ppat.1008902.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>Z</given-names></name>, <name><surname>Yi</surname><given-names>Y</given-names></name>, <name><surname>Luo</surname><given-names>X</given-names></name>, <name><surname>Xiong</surname><given-names>N</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Li</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis</article-title>. <source>J Med Virol</source>. <volume>2020</volume>:<fpage>1</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="ppat.1008902.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Broughton</surname><given-names>JP</given-names></name>, <name><surname>Deng</surname><given-names>X</given-names></name>, <name><surname>Yu</surname><given-names>G</given-names></name>, <name><surname>Fasching</surname><given-names>CL</given-names></name>, <name><surname>Singh</surname><given-names>J</given-names></name>, <name><surname>Streithorst</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Rapid detection of 2019 novel coronavirus SARS-CoV-2 using a CRISPR-based DETECTR lateral flow assay.</article-title>
<source>medRxiv.</source>
<year>2020</year>.</mixed-citation></ref><ref id="ppat.1008902.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Lassauni&#x000e8;re</surname><given-names>R</given-names></name>, <name><surname>Frische</surname><given-names>A</given-names></name>, <name><surname>Harboe</surname><given-names>ZB</given-names></name>, <name><surname>Nielsen</surname><given-names>AC</given-names></name>, <name><surname>Fomsgaard</surname><given-names>A</given-names></name>, <name><surname>Krogfelt</surname><given-names>KA</given-names></name>, <etal>et al</etal>
<article-title>Evaluation of nine commercial SARS-CoV-2 immunoassays.</article-title>
<source>medRxiv.</source>
<year>2020</year>.</mixed-citation></ref><ref id="ppat.1008902.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Wrapp</surname><given-names>D</given-names></name>, <name><surname>Wang</surname><given-names>N</given-names></name>, <name><surname>Corbett</surname><given-names>KS</given-names></name>, <name><surname>Goldsmith</surname><given-names>JA</given-names></name>, <name><surname>Hsieh</surname><given-names>CL</given-names></name>, <name><surname>Abiona</surname><given-names>O</given-names></name>, <etal>et al</etal>
<article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.</article-title>
<source>Science</source>. <year>2020</year>;<volume>367</volume>:<fpage>1260</fpage>&#x02013;<lpage>1263</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb2507</pub-id>
<?supplied-pmid 32075877?><pub-id pub-id-type="pmid">32075877</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Hoffmann</surname><given-names>M</given-names></name>, <name><surname>Kleine-Weber</surname><given-names>H</given-names></name>, <name><surname>Schroeder</surname><given-names>S</given-names></name>, <name><surname>Kr&#x000fc;ger</surname><given-names>N</given-names></name>, <name><surname>Herrler</surname><given-names>T</given-names></name>, <name><surname>Erichsen</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title>. <source>Cell</source>. <year>2020</year>;<volume>181</volume>:<fpage>271</fpage>&#x02013;<lpage>280</lpage>.e8. <pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id>
<?supplied-pmid 32142651?><pub-id pub-id-type="pmid">32142651</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Yan</surname><given-names>R</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Xia</surname><given-names>L</given-names></name>, <name><surname>Guo</surname><given-names>Y</given-names></name>, <name><surname>Zhou</surname><given-names>Q</given-names></name>. <article-title>Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2</article-title>. <source>Science</source>. <year>2020</year>;<volume>367</volume>:<fpage>1444</fpage>&#x02013;<lpage>1448</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb2762</pub-id>
<?supplied-pmid 32132184?><pub-id pub-id-type="pmid">32132184</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Kang</surname><given-names>S</given-names></name>, <name><surname>Yang</surname><given-names>M</given-names></name>, <name><surname>Hong</surname><given-names>Z</given-names></name>, <name><surname>Zhang</surname><given-names>L</given-names></name>, <name><surname>Huang</surname><given-names>Z</given-names></name>, <name><surname>Chen</surname><given-names>X</given-names></name>, <etal>et al</etal>
<article-title>Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites.</article-title>
<source>Acta Pharm Sin B.</source>
<year>2020</year>;<volume>10</volume>:<fpage>1228</fpage>&#x02013;<lpage>1238</lpage>. <pub-id pub-id-type="doi">10.1016/j.apsb.2020.04.009</pub-id>
<?supplied-pmid 32363136?><pub-id pub-id-type="pmid">32363136</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>L</given-names></name>, <name><surname>Lin</surname><given-names>D</given-names></name>, <name><surname>Sun</surname><given-names>X</given-names></name>, <name><surname>Curth</surname><given-names>U</given-names></name>, <name><surname>Drosten</surname><given-names>C</given-names></name>, <name><surname>Sauerhering</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved &#x003b1;-ketoamide inhibitors</article-title>. <source>Science</source>. <year>2020</year>;<volume>368</volume>:<fpage>409</fpage>&#x02013;<lpage>412</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb3405</pub-id>
<?supplied-pmid 32198291?><pub-id pub-id-type="pmid">32198291</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Gordon</surname><given-names>DE</given-names></name>, <name><surname>Jang</surname><given-names>GM</given-names></name>, <name><surname>Bouhaddou</surname><given-names>M</given-names></name>, <name><surname>Xu</surname><given-names>J</given-names></name>, <name><surname>Obernier</surname><given-names>K</given-names></name>, <name><surname>White</surname><given-names>KM</given-names></name>, <etal>et al</etal>
<article-title>A SARS-CoV-2 protein interaction map reveals targets for drug repurposing</article-title>. <source>Nature</source>. <year>2020</year>;<volume>583</volume>:<fpage>459</fpage>&#x02013;<lpage>468</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2286-9</pub-id>
<?supplied-pmid 32353859?><pub-id pub-id-type="pmid">32353859</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Shi</surname><given-names>J</given-names></name>, <name><surname>Wen</surname><given-names>Z</given-names></name>, <name><surname>Zhong</surname><given-names>G</given-names></name>, <name><surname>Yang</surname><given-names>H</given-names></name>, <name><surname>Wang</surname><given-names>C</given-names></name>, <name><surname>Huang</surname><given-names>B</given-names></name>, <etal>et al</etal>
<article-title>Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2</article-title>. <source>Science</source>. <year>2020</year>;<volume>368</volume>:<fpage>1016</fpage>&#x02013;<lpage>1020</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb7015</pub-id>
<?supplied-pmid 32269068?><pub-id pub-id-type="pmid">32269068</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Schlottau</surname><given-names>K</given-names></name>, <name><surname>Rissmann</surname><given-names>M</given-names></name>, <name><surname>Graaf</surname><given-names>A</given-names></name>, <name><surname>Sch&#x000f6;n</surname><given-names>J</given-names></name>, <name><surname>Sehl</surname><given-names>J</given-names></name>, <name><surname>Wylezich</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: an experimental transmission study</article-title>. <source>Lancet Microbe</source>. <year>2020</year>.</mixed-citation></ref><ref id="ppat.1008902.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Gao</surname><given-names>Q</given-names></name>, <name><surname>Bao</surname><given-names>L</given-names></name>, <name><surname>Mao</surname><given-names>H</given-names></name>, <name><surname>Wang</surname><given-names>L</given-names></name>, <name><surname>Xu</surname><given-names>K</given-names></name>, <name><surname>Yang</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Development of an inactivated vaccine candidate for SARS-CoV-2</article-title>. <source>Science</source>. <year>2020</year>;<volume>369</volume>:<fpage>eabc1932</fpage>.</mixed-citation></ref><ref id="ppat.1008902.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>J</given-names></name>, <name><surname>Tostanoski</surname><given-names>LH</given-names></name>, <name><surname>Peter</surname><given-names>L</given-names></name>, <name><surname>Mercado</surname><given-names>NB</given-names></name>, <name><surname>McMahan</surname><given-names>K</given-names></name>, <name><surname>Mahrokhian</surname><given-names>SH</given-names></name>, <etal>et al</etal>
<article-title>DNA vaccine protection against SARS-CoV-2 in rhesus macaques</article-title>. <source>Science</source>. <year>2020</year>:<fpage>eabc6284</fpage>.</mixed-citation></ref><ref id="ppat.1008902.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Boudewijns</surname><given-names>R</given-names></name>, <name><surname>Thibaut</surname><given-names>HJ</given-names></name>, <name><surname>Kaptein</surname><given-names>SJF</given-names></name>, <name><surname>Li</surname><given-names>R</given-names></name>, <name><surname>Vergote</surname><given-names>V</given-names></name>, <name><surname>Seldeslachts</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>STAT2 signaling as double-edged sword restricting viral dissemination but driving severe pneumonia in SARS-CoV-2 infected hamsters.</article-title>
<source>bioRxiv.</source>
<year>2020</year>.</mixed-citation></ref><ref id="ppat.1008902.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Weston</surname><given-names>S</given-names></name>, <name><surname>Haupt</surname><given-names>R</given-names></name>, <name><surname>Logue</surname><given-names>J</given-names></name>, <name><surname>Matthews</surname><given-names>K</given-names></name>, <name><surname>Frieman</surname><given-names>M</given-names></name>. <article-title>FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro.</article-title>
<source>bioRxiv.</source>
<year>2020</year>.</mixed-citation></ref><ref id="ppat.1008902.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>P</given-names></name>, <name><surname>Qi</surname><given-names>F</given-names></name>, <name><surname>Xu</surname><given-names>Y</given-names></name>, <name><surname>Li</surname><given-names>F</given-names></name>, <name><surname>Liu</surname><given-names>P</given-names></name>, <name><surname>Liu</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Age-related rhesus macaque models of COVID-19.</article-title>
<source>Animal Model Exp Med</source>. <year>2020</year>;<volume>3</volume>:<fpage>93</fpage>&#x02013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1002/ame2.12108</pub-id>
<?supplied-pmid 32318665?><pub-id pub-id-type="pmid">32318665</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Thao</surname><given-names>TTN</given-names></name>, <name><surname>Labroussaa</surname><given-names>F</given-names></name>, <name><surname>Ebert</surname><given-names>N</given-names></name>, <name><surname>V&#x02019;kovski</surname><given-names>P</given-names></name>, <name><surname>Stalder</surname><given-names>H</given-names></name>, <name><surname>Portmann</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform</article-title>. <source>Nature</source>. <year>2020</year>;<volume>582</volume>:<fpage>561</fpage>&#x02013;<lpage>565</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2294-9</pub-id>
<?supplied-pmid 32365353?><pub-id pub-id-type="pmid">32365353</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Jakhar</surname><given-names>D</given-names></name>, <name><surname>Kaur</surname><given-names>I</given-names></name>. <article-title>Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus</article-title>. <source>Nat Med</source>. <year>2020</year>;<volume>26</volume>:<fpage>632</fpage>.</mixed-citation></ref><ref id="ppat.1008902.ref049"><label>49</label><mixed-citation publication-type="other">U.S. Food &#x00026; Drug Administration. FDA statements on hydroxychloroquine and chloroquine. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or">https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or</ext-link>.</mixed-citation></ref><ref id="ppat.1008902.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>G</given-names></name>, <name><surname>De Clercq</surname><given-names>E</given-names></name>. <article-title>Therapeutic options for the 2019 novel coronavirus (2019-nCoV).</article-title>
<source>Nat Rev Drug Discov</source>. <year>2020</year>;<volume>19</volume>:<fpage>149</fpage>&#x02013;<lpage>150</lpage>. <pub-id pub-id-type="doi">10.1038/d41573-020-00016-0</pub-id>
<?supplied-pmid 32127666?><pub-id pub-id-type="pmid">32127666</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Riva</surname><given-names>L</given-names></name>, <name><surname>Yuan</surname><given-names>S</given-names></name>, <name><surname>Yin</surname><given-names>X</given-names></name>, <name><surname>Martin-Sancho</surname><given-names>L</given-names></name>, <name><surname>Matsunaga</surname><given-names>N</given-names></name>, <name><surname>Burgstaller</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>A large-scale drug repositioning survey for SARS-CoV-2 antivirals.</article-title>
<source>bioRxiv.</source>
<year>2020</year>.</mixed-citation></ref><ref id="ppat.1008902.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Ellinger</surname><given-names>B</given-names></name>, <name><surname>Bojkova</surname><given-names>D</given-names></name>, <name><surname>Zaliani</surname><given-names>A</given-names></name>, <name><surname>Cinatl</surname><given-names>J</given-names></name>, <name><surname>Claussen</surname><given-names>C</given-names></name>, <name><surname>Westhaus</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection.</article-title>
<source>Res Sq.</source>
<year>2020</year>.</mixed-citation></ref><ref id="ppat.1008902.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Touret</surname><given-names>F</given-names></name>, <name><surname>Gilles</surname><given-names>M</given-names></name>, <name><surname>Barral</surname><given-names>K</given-names></name>, <name><surname>Nougair&#x000e8;de</surname><given-names>A</given-names></name>, <name><surname>Decroly</surname><given-names>E</given-names></name>, <name><surname>de Lamballerie</surname><given-names>X</given-names></name>, <etal>et al</etal>
<article-title>In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication.</article-title>
<source>bioRxiv.</source>
<year>2020</year>.</mixed-citation></ref><ref id="ppat.1008902.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Zhou</surname><given-names>Y</given-names></name>, <name><surname>Hou</surname><given-names>Y</given-names></name>, <name><surname>Shen</surname><given-names>J</given-names></name>, <name><surname>Huang</surname><given-names>Y</given-names></name>, <name><surname>Martin</surname><given-names>W</given-names></name>, <name><surname>Cheng</surname><given-names>F</given-names></name>. <article-title>Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2.</article-title>
<source>Cell Discov.</source>
<year>2020</year>;<volume>6</volume>:<fpage>1</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1038/s41421-019-0132-8</pub-id>
<?supplied-pmid 31934347?><pub-id pub-id-type="pmid">31934347</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref055"><label>55</label><mixed-citation publication-type="other">Hinton DM. Remdesivir EUA Letter of Authorization. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/media/137564/download">https://www.fda.gov/media/137564/download</ext-link>.</mixed-citation></ref><ref id="ppat.1008902.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Duan</surname><given-names>K</given-names></name>, <name><surname>Liu</surname><given-names>B</given-names></name>, <name><surname>Li</surname><given-names>C</given-names></name>, <name><surname>Zhang</surname><given-names>H</given-names></name>, <name><surname>Yu</surname><given-names>T</given-names></name>, <name><surname>Qu</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Effectiveness of convalescent plasma therapy in severe COVID-19 patients</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2020</year>;<volume>117</volume>:<fpage>9490</fpage>&#x02013;<lpage>9496</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.2004168117</pub-id>
<?supplied-pmid 32253318?><pub-id pub-id-type="pmid">32253318</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Casadevall</surname><given-names>A</given-names></name>, <name><surname>Pirofski</surname><given-names>LA</given-names></name>. <article-title>The convalescent sera option for containing COVID-19</article-title>. <source>J Clin Invest</source>. <year>2020</year>;<volume>130</volume>:<fpage>1545</fpage>&#x02013;<lpage>1548</lpage>. <pub-id pub-id-type="doi">10.1172/JCI138003</pub-id>
<?supplied-pmid 32167489?><pub-id pub-id-type="pmid">32167489</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref058"><label>58</label><mixed-citation publication-type="other">Takeda News Releases. Takeda Initiates Development of a Plasma-Derived Therapy for COVID-19. 2020. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.takeda.com/newsroom/newsreleases/2020/takeda-initiates-development-of-a-plasma-derived-therapy-for-covid-19/">https://www.takeda.com/newsroom/newsreleases/2020/takeda-initiates-development-of-a-plasma-derived-therapy-for-covid-19/</ext-link>.</mixed-citation></ref><ref id="ppat.1008902.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>Tian</surname><given-names>X</given-names></name>, <name><surname>Li</surname><given-names>C</given-names></name>, <name><surname>Huang</surname><given-names>A</given-names></name>, <name><surname>Xia</surname><given-names>S</given-names></name>, <name><surname>Lu</surname><given-names>S</given-names></name>, <name><surname>Shi</surname><given-names>Z</given-names></name>, <etal>et al</etal>
<article-title>Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.</article-title>
<source>Emerg Microbes Infect.</source>
<year>2020</year>;<volume>9</volume>:<fpage>382</fpage>&#x02013;<lpage>385</lpage>. <pub-id pub-id-type="doi">10.1080/22221751.2020.1729069</pub-id>
<?supplied-pmid 32065055?><pub-id pub-id-type="pmid">32065055</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref060"><label>60</label><mixed-citation publication-type="journal"><name><surname>Yuan</surname><given-names>M</given-names></name>, <name><surname>Wu</surname><given-names>NC</given-names></name>, <name><surname>Zhu</surname><given-names>X</given-names></name>, <name><surname>Lee</surname><given-names>C-CD</given-names></name>, <name><surname>So</surname><given-names>RTY</given-names></name>, <name><surname>Lv</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV</article-title>. <source>Science.</source>
<year>2020</year>;<volume>368</volume>:<fpage>630</fpage>&#x02013;<lpage>633</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb7269</pub-id>
<?supplied-pmid 32245784?><pub-id pub-id-type="pmid">32245784</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref061"><label>61</label><mixed-citation publication-type="journal"><name><surname>Pinto</surname><given-names>D</given-names></name>, <name><surname>Park</surname><given-names>Y-J</given-names></name>, <name><surname>Beltramello</surname><given-names>M</given-names></name>, <name><surname>Walls</surname><given-names>AC</given-names></name>, <name><surname>Tortorici</surname><given-names>MA</given-names></name>, <name><surname>Bianchi</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Structural and functional analysis of a potent sarbecovirus neutralizing antibody.</article-title>
<source>bioRxiv.</source>
<year>2020</year>.</mixed-citation></ref><ref id="ppat.1008902.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>C</given-names></name>, <name><surname>Li</surname><given-names>W</given-names></name>, <name><surname>Drabek</surname><given-names>D</given-names></name>, <name><surname>Okba</surname><given-names>NMA</given-names></name>, <name><surname>van Haperen</surname><given-names>R</given-names></name>, <name><surname>Osterhaus</surname><given-names>ADME</given-names></name>, <etal>et al</etal>
<article-title>A human monoclonal antibody blocking SARS-CoV-2 infection.</article-title>
<source>Nat Commun.</source>
<year>2020</year>;<volume>11</volume>:<fpage>2251</fpage>
<pub-id pub-id-type="doi">10.1038/s41467-020-16256-y</pub-id>
<?supplied-pmid 32366817?><pub-id pub-id-type="pmid">32366817</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref063"><label>63</label><mixed-citation publication-type="journal"><name><surname>Rogers</surname><given-names>TF</given-names></name>, <name><surname>Zhao</surname><given-names>F</given-names></name>, <name><surname>Huang</surname><given-names>D</given-names></name>, <name><surname>Beutler</surname><given-names>N</given-names></name>, <name><surname>Burns</surname><given-names>A</given-names></name>, <name><surname>He</surname><given-names>W</given-names></name>, <etal>et al</etal>
<article-title>Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model</article-title>. <source>Science</source>. <year>2020</year>:<fpage>eabc7520</fpage>.</mixed-citation></ref><ref id="ppat.1008902.ref064"><label>64</label><mixed-citation publication-type="journal"><name><surname>Brouwer</surname><given-names>PJM</given-names></name>, <name><surname>Caniels</surname><given-names>TG</given-names></name>, <name><surname>van der Straten</surname><given-names>K</given-names></name>, <name><surname>Snitselaar</surname><given-names>JL</given-names></name>, <name><surname>Aldon</surname><given-names>Y</given-names></name>, <name><surname>Bangaru</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability</article-title>. <source>Science</source>. <year>2020</year>:<fpage>eabc5902</fpage>.</mixed-citation></ref><ref id="ppat.1008902.ref065"><label>65</label><mixed-citation publication-type="other">Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19). Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04283461">https://clinicaltrials.gov/ct2/show/NCT04283461</ext-link>.</mixed-citation></ref><ref id="ppat.1008902.ref066"><label>66</label><mixed-citation publication-type="journal"><name><surname>Orellana</surname><given-names>C</given-names></name>, <name><surname>Phase</surname><given-names>I</given-names></name>. <article-title>SARS vaccine trial in China.</article-title>
<source>Lancet Infect Dis</source>. <year>2004</year>;<volume>4</volume>:<fpage>388</fpage>
<pub-id pub-id-type="doi">10.1016/s1473-3099(04)01071-0</pub-id>
<?supplied-pmid 15252932?><pub-id pub-id-type="pmid">15252932</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref067"><label>67</label><mixed-citation publication-type="other">BioRender. COVID-19 Vaccine Tracker. Available from: <ext-link ext-link-type="uri" xlink:href="https://biorender.com/covid-vaccine-tracker">https://biorender.com/covid-vaccine-tracker</ext-link>.</mixed-citation></ref><ref id="ppat.1008902.ref068"><label>68</label><mixed-citation publication-type="journal"><name><surname>Lurie</surname><given-names>N</given-names></name>, <name><surname>Saville</surname><given-names>M</given-names></name>, <name><surname>Hatchett</surname><given-names>R</given-names></name>, <name><surname>Halton</surname><given-names>J</given-names></name>. <article-title>Developing Covid-19 vaccines at pandemic speed</article-title>. <source>N Engl J Med</source>. <year>2020</year>.</mixed-citation></ref><ref id="ppat.1008902.ref069"><label>69</label><mixed-citation publication-type="journal"><name><surname>Yozwiak</surname><given-names>NL</given-names></name>, <name><surname>Schaffner</surname><given-names>SF</given-names></name>, <name><surname>Sabeti</surname><given-names>PC</given-names></name>. <article-title>Data sharing: make outbreak research open access</article-title>. <source>Nature</source>
<year>2015</year>;<volume>518</volume>:<fpage>477</fpage>&#x02013;<lpage>479</lpage>. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.nature.com/news/data-sharing-make-outbreak-research-open-access-1.16966">https://www.nature.com/news/data-sharing-make-outbreak-research-open-access-1.16966</ext-link>. <pub-id pub-id-type="doi">10.1038/518477a</pub-id>
<?supplied-pmid 25719649?><pub-id pub-id-type="pmid">25719649</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref070"><label>70</label><mixed-citation publication-type="other">Centers for Disease Control and Prevention. COVID-19 Databases and Journals. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/library/researchguides/2019novelcoronavirus/databasesjournals.html">https://www.cdc.gov/library/researchguides/2019novelcoronavirus/databasesjournals.html</ext-link>.</mixed-citation></ref><ref id="ppat.1008902.ref071"><label>71</label><mixed-citation publication-type="other">Worldometer: Coronavirus. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.worldometers.info/coronavirus/">https://www.worldometers.info/coronavirus/</ext-link>.</mixed-citation></ref><ref id="ppat.1008902.ref072"><label>72</label><mixed-citation publication-type="other">nCoV2019.live. Available from: <ext-link ext-link-type="uri" xlink:href="https://ncov2019.live/">https://ncov2019.live/</ext-link>.</mixed-citation></ref><ref id="ppat.1008902.ref073"><label>73</label><mixed-citation publication-type="other">HealthMap COVID-19. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.healthmap.org/covid-19/">https://www.healthmap.org/covid-19/</ext-link>.</mixed-citation></ref><ref id="ppat.1008902.ref074"><label>74</label><mixed-citation publication-type="other">Center for Systems Science and Engineering at Johns Hopkins University. COVID-19 Dashboard. Available from: <ext-link ext-link-type="uri" xlink:href="https://coronavirus.jhu.edu/map.html">https://coronavirus.jhu.edu/map.html</ext-link>.</mixed-citation></ref><ref id="ppat.1008902.ref075"><label>75</label><mixed-citation publication-type="other">Open COVID Pledge. Available from: <ext-link ext-link-type="uri" xlink:href="https://opencovidpledge.org/about">https://opencovidpledge.org/about</ext-link>.</mixed-citation></ref><ref id="ppat.1008902.ref076"><label>76</label><mixed-citation publication-type="other">Financial Times. AbbVie drops patent rights for Kaletra antiviral treatment. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.ft.com/content/5a7a9658-6d1f-11ea-89df-41bea055720b">https://www.ft.com/content/5a7a9658-6d1f-11ea-89df-41bea055720b</ext-link>.</mixed-citation></ref><ref id="ppat.1008902.ref077"><label>77</label><mixed-citation publication-type="other">Netherlands Authority for Consumers and Markets. ACM has confidence in commitments made by Roche to help solve problems with test materials. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.acm.nl/en/publications/acm-has-confidence-commitments-made-roche-help-solve-problems-test-materials">https://www.acm.nl/en/publications/acm-has-confidence-commitments-made-roche-help-solve-problems-test-materials</ext-link>.</mixed-citation></ref><ref id="ppat.1008902.ref078"><label>78</label><mixed-citation publication-type="other">Operation Shields Up! Available from: <ext-link ext-link-type="uri" xlink:href="https://www.opshieldsup.org/about">https://www.opshieldsup.org/about</ext-link>.</mixed-citation></ref><ref id="ppat.1008902.ref079"><label>79</label><mixed-citation publication-type="other">Brewdog Hand Sanitiser. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.brewdog.com/uk/hand-sanitiser">https://www.brewdog.com/uk/hand-sanitiser</ext-link>.</mixed-citation></ref><ref id="ppat.1008902.ref080"><label>80</label><mixed-citation publication-type="other">Platform for European Preparedness Against (Re-)emerging Epidemics. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.prepare-europe.eu/">https://www.prepare-europe.eu/</ext-link>.</mixed-citation></ref><ref id="ppat.1008902.ref081"><label>81</label><mixed-citation publication-type="journal"><name><surname>van der Hoek</surname><given-names>L</given-names></name>, <name><surname>Verschoor</surname><given-names>E</given-names></name>, <name><surname>Beer</surname><given-names>M</given-names></name>, <name><surname>H&#x000f6;per</surname><given-names>D</given-names></name>, <name><surname>Wernike</surname><given-names>K</given-names></name>, <name><surname>Van Ranst</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Host switching pathogens, infectious outbreaks and zoonosis: a Marie Sk&#x00142;odowska-Curie innovative training network (HONOURs).</article-title>
<source>Virus Res</source>. <year>2018</year>;<volume>257</volume>:<fpage>120</fpage>&#x02013;<lpage>124</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2018.09.002</pub-id>
<?supplied-pmid 30316331?><pub-id pub-id-type="pmid">30316331</pub-id></mixed-citation></ref><ref id="ppat.1008902.ref082"><label>82</label><mixed-citation publication-type="other">World Health Organization. &#x0201c;Solidarity&#x0201d; clinical trial for COVID-19 treatments. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments</ext-link>.</mixed-citation></ref><ref id="ppat.1008902.ref083"><label>83</label><mixed-citation publication-type="other">World Health Organization. Global health ethics: resources on ethics and COVID-19. 2020. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/ethics/topics/outbreaks-emergencies/covid-19/en/">https://www.who.int/ethics/topics/outbreaks-emergencies/covid-19/en/</ext-link>.</mixed-citation></ref><ref id="ppat.1008902.ref084"><label>84</label><mixed-citation publication-type="journal"><collab>COVID-19 Clinical Research Coalition</collab>. <article-title>Global coalition to accelerate COVID-19 clinical research in resource-limited settings.</article-title>
<source>The Lancet</source>. <year>2020</year>;<volume>395</volume>:<fpage>1322</fpage>&#x02013;<lpage>1325</lpage>.</mixed-citation></ref></ref-list></back></article>